<code id='30E11EC9E9'></code><style id='30E11EC9E9'></style>
    • <acronym id='30E11EC9E9'></acronym>
      <center id='30E11EC9E9'><center id='30E11EC9E9'><tfoot id='30E11EC9E9'></tfoot></center><abbr id='30E11EC9E9'><dir id='30E11EC9E9'><tfoot id='30E11EC9E9'></tfoot><noframes id='30E11EC9E9'>

    • <optgroup id='30E11EC9E9'><strike id='30E11EC9E9'><sup id='30E11EC9E9'></sup></strike><code id='30E11EC9E9'></code></optgroup>
        1. <b id='30E11EC9E9'><label id='30E11EC9E9'><select id='30E11EC9E9'><dt id='30E11EC9E9'><span id='30E11EC9E9'></span></dt></select></label></b><u id='30E11EC9E9'></u>
          <i id='30E11EC9E9'><strike id='30E11EC9E9'><tt id='30E11EC9E9'><pre id='30E11EC9E9'></pre></tt></strike></i>

          focus

          focus

          author:leisure time    Page View:45783
          Stock exchange
          Drew Angerer/Getty Images

          Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development. 

          The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

          advertisement

          In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Bill would stop addiction treatment from triggering child abuse inquiry
          Bill would stop addiction treatment from triggering child abuse inquiry

          WORCESTER,MA-6/7/2023KaylaFordhugsher2-year-oldson,Memphis,intheiryardinWorcester,MA.ErinClark/Globe

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          3 questions for the future of Biden's cancer moonshot

          PresidentJoeBidenEliseAmendola/APWASHINGTON—ThelatestphaseofPresidentBiden’sCancerMoonshotinitiative